Validation of IGA*BSA in Assessing Disease Severity and Response in Patients with Atopic Dermatitis: A Retrospective Cohort Study in China
Dermatitis® · 2025
DOI: 10.1089/derm.2024.0226 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Dermatitis®, 2025. Verfasst von Chener Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Severity of Illness Index, Body Surface Area. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Accurate evaluation of atopic dermatitis (AD) severity is crucial to determine and adjust treatment options. Previous studies have found the product of Investigator’s Global Assessment (IGA) and affected body surface area (BSA) to be a simple tool, which requires further verification.
Objective
To determine the validity of IGA*BSA in assessing the severity of AD across all age, sex, BMI and disease severity groups.
Method
We performed a retrospective study of AD using data from a national cohort (China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project).
Results
Overall, 3051 participants were included in the final analysis. IGA*BSA correlated better with objective measures than with subjective measures. IGA*BSA significantly correlated with Eczema Area and Severity Index (EASI) (r = 0.81), which was stronger than either IGA or BSA alone with EASI, regardless of age, sex, Body Mass Index (BMI), and disease severity groups. Besides, IGA*BSA mild, moderate, and severe groups were associated with significantly higher scores of other assessments and had moderate to fair concordance with other assessments severity strata. At follow-up, the concordance of improvement between IGA*BSA 50/75/90 and EASI 50/75/90 was observed (ĸ = 0.65, 0.62, 0.58, respectively).
Conclusion
IGA*BSA appears to be a valid objective assessment of AD severity and improvement over time across all age, sex, BMI, and disease severity subgroups in the clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- From the Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China.
- Shantou University Medical College, Shantou, China.
- National Clinical Research Center for Skin and Immune Disease, Beijing, China.
ORCID-Profile: Chener Yang, Jiaying Chen
Zitieren
APA
Yang, C., Wu, X., He, J., Liao, Y., Chen, J., & Dou, X. (2025). Validation of IGA*BSA in Assessing Disease Severity and Response in Patients with Atopic Dermatitis: A Retrospective Cohort Study in China. Dermatitis®. https://doi.org/10.1089/derm.2024.0226
Vancouver
Yang C, Wu X, He J, Liao Y, Chen J, Dou X. Validation of IGA*BSA in Assessing Disease Severity and Response in Patients with Atopic Dermatitis: A Retrospective Cohort Study in China. Dermatitis®. 2025. doi:10.1089/derm.2024.0226
BibTeX
@article{Yang2025,
author = {Yang, Chener and Wu, Xia and He, Jing and Liao, Yan and Chen, Jiaying and Dou, Xia},
title = {Validation of IGA*BSA in Assessing Disease Severity and Response in Patients with Atopic Dermatitis: A Retrospective Cohort Study in China},
journal = {Dermatitis®},
year = {2025},
doi = {10.1089/derm.2024.0226}
}
EUVIMED